🟢 Neumora Therapeutics is trading 5% up in pre-market with no identified company explanation

Neumora Therapeutics is trading at $0.43, up 5.03%, with no identified company announcement explaining the October 23 pre-market rise.

• Recent coverage reported that navacaprant failed the KOASTAL-1 Phase 3 trial, but that negative news does not explain the gain.
• Supplied market context showed only modest index declines this morning. Recent closing prices reflect several volatile sessions, including a sharp decline followed by a rebound.